EMA (EU)
GUIDANCE FINAL
Concept paper on revision of: Guideline on similar biological medicinal products, CHMP/437/04 Rev.1
Published: 7/22/2026Detected: 7/22/2026
Summary preview
Revises EMA’s biosimilar guideline framework to reflect post-2015 scientific progress, including a tailored clinical approach for comparative efficacy studies (CES) and ongoing alignment with the ICH M18 approach.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
clinical
manufacturing
quality
clinical
safety
labeling
#biosimilar
#comparative efficacy studies
#tailored clinical approach
#ICH M18
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026